Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in Recurrent Non-Small Cell Lung Cancer
NCT00179686Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in non-small cell lung cancer (NSCLC), sponsored by Celgene Corporation. Started Mar 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00179686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179686.